Predicted trends shaping obesity drug development in 2027

The obesity treatment landscape is evolving at an unprecedented pace. The success of GLP-1 receptor agonists and dual incretin therapies has transformed expectations for obesity treatment, accelerated investment across the sector and expanded the pipeline of novel therapies.^¹⁻³

Just a few years ago, discussions in obesity drug development focused largely on how much weight patients could lose. Today, sponsors, researchers and regulators are increasingly asking broader questions. How durable are treatment effects? What constitutes high-quality weight loss? Can therapies improve long-term health outcomes beyond the scale? And what will the next generation of obesity medicines look like?

As the industry looks ahead to 2027, several trends are expected to influence the future of obesity research and clinical development.

Long-term weight maintenance will become a primary measure of success

The remarkable efficacy demonstrated by recent obesity therapies has changed the standard for weight reduction. However, clinical experience has reinforced an important reality: losing weight and maintaining weight loss are two very different challenges.

Research continues to demonstrate that obesity is a chronic disease characterized by biological mechanisms that actively promote weight regain. Following weight loss, physiological adaptations can increase appetite and reduce energy expenditure, making long-term maintenance particularly difficult. Studies have shown that weight regain commonly occurs following treatment discontinuation, highlighting the need for obesity to be managed as a long-term condition rather than a short-term intervention.^⁴

As a result, obesity clinical trials may increasingly place greater emphasis on durability of response, treatment persistence and post-treatment outcomes. Sponsors are likely to face growing expectations to demonstrate not only whether a therapy can reduce body weight, but also whether those benefits can be maintained over time.

High-quality weight loss will receive greater attention

As therapies deliver increasingly impressive levels of weight reduction, researchers are looking beyond total weight loss to better understand what that weight loss actually represents.

Historically, changes in body weight and BMI have served as the primary efficacy metrics in obesity trials. While these measurements remain important, they do not fully capture treatment benefit. Increasing evidence suggests that body composition may play an important role in determining long-term outcomes, with growing attention being paid to the preservation of lean mass, maintenance of physical function and preferential reduction of adipose tissue.^⁵⁻⁷

This shift is likely to influence future clinical development programs. Sponsors may increasingly incorporate body composition assessments, functional measures and metabolic outcomes into study designs. Questions surrounding the definition of meaningful clinical benefit are expected to become increasingly important as regulators, healthcare providers and payers evaluate the broader value of obesity therapies.

Innovation will continue to expand beyond traditional incretins

The success of GLP-1 therapies has created tremendous momentum across obesity drug development, but innovation is rapidly expanding beyond first-generation incretin therapies. Researchers are now evaluating a wide range of approaches, including dual agonists, triple agonists, oral therapies and compounds targeting entirely different biological pathways. One of the most widely discussed examples is retatrutide, a triple agonist targeting GLP-1, GIP and glucagon receptors that demonstrated substantial weight loss in a Phase II study.^⁸

At the same time, development programs are increasingly exploring mechanisms related to energy expenditure, adipose tissue biology, muscle preservation and metabolic regulation. These approaches reflect a growing recognition that obesity is a biologically complex disease that may benefit from multiple therapeutic mechanisms rather than a single pathway.

This diversification of the obesity pipeline may ultimately create opportunities for more personalized treatment strategies as sponsors seek to differentiate assets in an increasingly competitive market.

Oral therapies could reshape the treatment experience

While efficacy remains critical, patient experience is becoming an increasingly important consideration in obesity treatment. Injectable therapies have redefined expectations for weight loss, but they can also create challenges related to convenience, treatment burden and long-term adherence. As a result, considerable investment is being directed toward oral obesity therapies.

Recent clinical data for oral GLP-1 receptor agonists, including orforglipron, suggest that effective oral treatment options may become an increasingly important part of the obesity landscape.^⁹ Such therapies have the potential to expand access, improve convenience and provide additional treatment options for patients who may be reluctant to initiate or continue injectable treatment.

For sponsors, this growing focus on patient experience may introduce new considerations for clinical trial design, adherence monitoring and long-term treatment strategies.

Obesity treatment will increasingly focus on health outcomes

Perhaps the most significant shift taking place in obesity drug development is the move away from viewing obesity solely as a weight-management issue. The growing body of evidence linking obesity with cardiovascular disease, Type 2 diabetes, metabolic dysfunction-associated steatohepatitis (MASH), chronic kidney disease, sleep apnea and other chronic conditions has increased attention on broader health outcomes. ^¹⁰ As a result, future obesity therapies may be evaluated not only on their ability to reduce body weight, but also on their impact on cardiometabolic risk, overall health and quality of life.

The SELECT trial provided an important step in this evolution, demonstrating cardiovascular benefit with semaglutide in people with overweight or obesity and established cardiovascular disease, even in the absence of diabetes. ^¹⁰ These findings have helped reinforce the view that effective obesity treatment can influence outcomes that extend far beyond weight reduction alone.

The industry's focus is therefore gradually shifting from weight management toward long-term health improvement, creating new opportunities and new challenges for future obesity drug development.

The future of obesity drug development: what sponsors should expect

The obesity market is entering a new phase of innovation. While the past decade focused on proving that meaningful weight loss could be achieved pharmacologically, the next decade will likely focus on optimizing the long-term impact of those therapies. Durable weight maintenance, body composition, treatment adherence, patient experience and meaningful health outcomes are expected to play an increasingly important role in determining clinical and commercial success.

For sponsors, these changes present both opportunity and complexity. As expectations continue to rise, successful therapies may ultimately be defined not simply by how much weight patients lose, but by how effectively they help patients maintain those benefits and achieve meaningful improvements in long-term health.

Learn more about how Fortrea can help advance your obesity therapeutic development.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. 
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. 
3. World Obesity Federation. World Obesity Atlas 2025. 
4. Moiz A, Filion KB, Knäuper B, et al. Weight Maintenance After Discontinuation of GLP-1 Therapies. eClinicalMedicine. 2026. 
5. von Haehling S, Sato R, Langer H, , et al. Muscle Loss in Obesity Therapy as a Therapeutic Target: Trial Design and Endpoints for Regulatory Discussions. J Cachexia Sarcopenia Muscle. 2025 
6. Argyrakopoulou G, Gitsi E, Konstantinidou SK, Kokkinos A. The effect of obesity pharmacotherapy on body composition, including muscle mass. Int J Obes (Lond). 2025;49(3):381-387. doi:10.1038/s41366-024-01533-3 
7. Salmón-Gómez L, Catalán V, Frühbeck G, Gómez-Ambrosi J. Relevance of body composition in phenotyping the obesities. Rev Endocr Metab Disord. 2023;24(5):809-823. doi:10.1007/s11154-023-09796-3 
8. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. 2023;389(6):514-526.